We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+4.05%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$6.32B
AUM Growth
+$456M
(+7.8%)
Cap. Flow
+$224M
Cap. Flow
% of AUM
3.55%
Top 10 Holdings %
Top 10 Hldgs %
17.62%
Holding
844
New
72
Increased
349
Reduced
257
Closed
60
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$37.6M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$29.3M |
| 3 |
Biogen
BIIB
|
+$27.4M |
| 4 |
Home Depot
HD
|
+$22.7M |
| 5 |
Cisco
CSCO
|
+$21.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan Chase
JPM
|
+$23.6M |
| 2 |
TJX Companies
TJX
|
+$19.3M |
| 3 |
FedEx
FDX
|
+$16.4M |
| 4 |
Intuit
INTU
|
+$14.7M |
| 5 |
Corning
GLW
|
+$13.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.18% |
| 2 | Technology | 17.19% |
| 3 | Financials | 12.85% |
| 4 | Consumer Discretionary | 10.2% |
| 5 | Communication Services | 8.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RGLS
701
DELISTED
Regulus Therapeutics
RGLS
| $330K | 0.01% |
4,167
| – | – |
|
|
B
702
Barrick Mining
B
$62.2B
| $324K | 0.01% |
24,646
-64,840
| -72% | -$850K |
|
703
Voya Financial
VOYA
$8.94B
| $324K | 0.01% |
6,898
+1,097
| +19% | +$56.8K |
|
704
Brixmor Property Group
BRX
$9.95B
| $320K | 0.01% |
18,358
+5,823
| +46% | +$90.5K |
|
705
Pinnacle West Capital
PNW
$12.9B
| $318K | 0.01% |
3,946
-61,542
| -94% | -$4.81M |
|
|
CEO
706
DELISTED
CNOOC Limited
CEO
| $318K | 0.01% |
+1,857
| New | +$309K |
|
707
Petrobras
PBR
$121B
| $304K | ﹤0.01% |
30,353
+13,918
| +85% | +$178K |
|
|
FL
708
DELISTED
Foot Locker
FL
| $302K | ﹤0.01% |
5,742
-154,630
| -96% | -$7.48M |
|
709
iShares Silver Trust
SLV
$28.1B
| $298K | ﹤0.01% |
19,650
+4,650
| +31% | +$72.4K |
|
710
Henry Schein
HSIC
$9.74B
| $291K | ﹤0.01% |
5,113
-38
| -0.7% | -$2.14K |
|
711
Accuray
ARAY
$28.4M
| $287K | ﹤0.01% |
70,000
| – | – |
|
|
CSOD
712
DELISTED
Cornerstone OnDemand, Inc.
CSOD
| $285K | ﹤0.01% |
6,000
-9,000
| -60% | -$420K |
|
713
Restaurant Brands International
QSR
$25.1B
| $283K | ﹤0.01% |
4,688
+259
| +6% | +$14.8K |
|
714
Franco-Nevada
FNV
$41.4B
| $282K | ﹤0.01% |
3,870
-5
| -0.1% | -$354 |
|
715
State Street SPDR S&P Biotech ETF
XBI
$10.1B
| $279K | ﹤0.01% |
+2,930
| New | +$269K |
|
716
Curis
CRIS
$9.53M
| $277K | ﹤0.01% |
400
| – | – |
|
717
Infosys
INFY
$45B
| $277K | ﹤0.01% |
28,480
+1,440
| +5% | +$12.9K |
|
718
Jones Lang LaSalle
JLL
$15.1B
| $277K | ﹤0.01% |
+1,667
| New | +$283K |
|
719
AutoNation
AN
$6.97B
| $269K | ﹤0.01% |
5,538
| – | – |
|
720
OGE Energy
OGE
$10.3B
| $254K | ﹤0.01% |
7,220
-15,786
| -69% | -$530K |
|
721
Andersons Inc
ANDE
$2.65B
| $239K | ﹤0.01% |
7,000
| – | – |
|
|
FSTX
722
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| $237K | ﹤0.01% |
5,000
| – | – |
|
723
Ameren
AEE
$31.5B
| $236K | ﹤0.01% |
3,877
-15,851
| -80% | -$911K |
|
724
SL Green Realty
SLG
$3.88B
| $236K | ﹤0.01% |
2,422
| – | – |
|
725
Insperity
NSP
$1.85B
| $233K | ﹤0.01% |
+2,451
| New | +$211K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2018 Portfolio in Review
As of Q2 2018, Candriam SCA held 844 positions worth $6.32B, up 7.8% from $5.86B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Candriam SCA deployed $224M of net new capital in Q2 2018, opening 72 new positions and adding to 349 existing holdings. Its largest new stake was Broadcom: 1,532,450 shares worth $37.2M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 23% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was JPMorgan Chase, an estimated $23.6M trimmed.
- Candriam SCA's largest Q2 2018 buy was Broadcom: 1,532,450 shares worth $37.2M.
- Candriam SCA added most to Bristol-Myers Squibb in Q2 2018, an estimated $29.3M increase.
- Candriam SCA's biggest Q2 2018 reduction was JPMorgan Chase, cutting an estimated $23.6M.
- Candriam SCA fully exited Monsanto Co in Q2 2018, selling an estimated $11.5M.
- Candriam SCA's ten largest holdings make up 18% of its $6.32B portfolio in Q2 2018.
- Candriam SCA opened 72 new positions and closed 60 in Q2 2018.
- Candriam SCA's portfolio value rose 7.8% quarter-over-quarter to $6.32B.
Based on Candriam SCA's 13F filing for Q2 2018, filed 14 Aug 2018.